Products for Research Use Only

Nelfinavir

CAT: 0804-HY-15287-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15287-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nelfinavir (AG-1341) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection. Nelfinavir is a broad-spectrum, anticancer agent[1][2][3].
CAS Number
159989-64-7
Product Name Alternative
AG1341
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HIV; HIV Protease
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/nelfinavir.html
Purity
98.65
Solubility
DMSO : ≥ 100 mg/mL
Smiles
[H][C@]12C[C@@H](C(NC(C)(C)C)=O)N(C[C@H]([C@@H](NC(C3=C(C)C(O)=CC=C3)=O)CSC4=CC=CC=C4)O)C[C@@]1([H])CCCC2
Molecular Formula
C32H45N3O4S
Molecular Weight
567.78
Precautions
H302, H315, H319, H335
References & Citations
[1]Mondal D, et al. Nelfinavir suppresses signaling and nitric oxide production by human aortic endothelial cells: protective effects of thiazolidinediones. Ochsner J. 2013 Spring;13 (1) :76-90.|[2]Kaldor SW, et al. Nelfinavir mesylate (AG1343) : a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40 (24) :3979-85.|[3]Gills JJ, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that inducesendoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res. 2007 Sep 1;13 (17) :5183-94.|[4]Bono C, et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 2012;97 (7) :1101‐1109.|[5]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
HIV-1
Citation 01
Antimicrob Agents Chemother. 2020 Aug 20;64 (9) :e00872-20.|Antiviral Res. 2022 Jun;202:105311.|bioRxiv. 2020 May.|bioRxiv. 2024 November 03.|Int J Antimicrob Agents. 2019 Dec;54 (6) :814-819.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|PLoS One. 2015 Aug 11;10 (8) :e0134707. |bioRxiv. 2021 Feb 1.|Cell Signal. 2020 Nov;75:109775.|Cells. 2022 Nov 12;11 (22) :3580.|Nat Commun. 2020 Sep 4;11 (1) :4417.|Patent. US20250123269A1.|Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|Viruses. 2022 Jun 23;14 (7) :1369.